]>
IRCT20220107053656N2 IRCT 2024-05-30 Tehran University of Medical Sciences The effect of Aesculus hippocastanum extract on the prevention of phlebitis induced by peripheral intravenous catheters Investigating the effect Aesculus hippocastanum extract on the prevention of phlebitis induced by peripheral intravenous catheters 2024-07-30 anticipated 100 Complete https://irct.ir/trial/75696 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Sampling will be done as available and 100 patients will be divided into two intervention and control groups (50 people in each group) by simple random allocation using block of four software, Blinding description: This study is a randomized and double-blind clinical trial (researchers and patients). In this way, the filling of the containers containing worms was done by someone other than the researcher or the sampler in the laboratory, and the containers of worms were named A and B for blinding, but blinding was not done for the statician. N/A Phlebitis induced by peripheral intravenous catheters. After the placement of peripheral catheters (Angioket No. 20) in the test group, Indian chestnut extract (Worm Worm) on the skin of the angioket insertion site measuring 3x3 cm and in the placebo cream control group, on the skin of the angioket insertion site measuring 3x3 cm centimeter will be placed and it will be covered by a sterile cover (angioket glue). Daru Nama cream will be prepared by the pharmaceutical laboratory of Iranian School of Medical Sciences in Tehran. In order to blind patients and researchers to the intervention, both cream and placebo will be packed in similar containers and will be provided to the researcher. The occurrence of phlebitis and its degrees will be checked within 72 hours from the time of placing angioket and cream, at zero, 24 and 48 hours.The examination of the position in 24-hour intervals in terms of the occurrence and severity of phlebitis will be done by one of the researchers and one of the colleagues working in the relevant department to ensure reliability between the two evaluators. Based on the study design and ethical considerations, in both groups after examining the position using the visual scale of phlebitis in terms of its development and severity, the samples will be excluded from the study as soon as grade 2 or more phlebitis develops in them, and only samples They will remain in groups with phlebitis of 0 and 1. No - There is not a plan to make this available Justification or reason for not sharing IPD is No more information
public Arpi Manookian
Department of medical-surgical nursing School of Nursing and Midwifery of Tehran University of Medical Sciences, East Nosrat street
Tehran Iran (Islamic Republic of) 1419733171 +98 21 6692 7171 ar-manookian@sina.tums.ac.ir Tehran University of Medical Sciences scientific Arpi Manookian
Department of medical-surgical nursing School of Nursing and Midwifery of Tehran University of Medical Sciences, East Nosrat street
Tehrah Iran (Islamic Republic of) 1419733171 +98 21 6692 7171 ar-manookian@sina.tums.ac.ir Tehran University of Medical Sciences Iran (Islamic Republic of) Hospitalization in the wards of Shariati Hospital for at least 72 hours Age between 18 and 60 years IV-line implantation in a vein of the upper limb in a place without signs of phlebitis 72-hour IV-line implantation Patient being awake 18 years 60 years Both Suffering from diabetes mellitus Suffering from skin disorders and types of eczema Suffering from systemic vascular disease Suffering from severe anemia Suffering from immunodeficiency diseases Allergic to iv-line adhesive Undergoing chemotherapy Receiving oral non-steroidal anti-inflammatory drugs, injections and suppositories Receiving intravenous amiodarone, and heparin and nitroglycerin Suffering from acute and chronic infectious diseases Having fever and receiving antibiotic treatment to eliminate fever Allergic to chestnut products Prevention After the placement of peripheral catheters (Angioket No. 20) in the test group, Indian chestnut extract (Worm Worm) on the skin of the angioket insertion site measuring 3x3 cm and in the placebo cream control group, on the skin of the angioket insertion site measuring 3x3 cm centimeter will be placed and it will be covered by a sterile cover (angioket glue). Daru Nama cream will be prepared by the pharmaceutical laboratory of Iranian School of Medical Sciences in Tehran. In order to blind patients and researchers to the intervention, both cream and placebo will be packed in similar containers and will be provided to the researcher. The occurrence of phlebitis and its degrees will be checked within 72 hours from the time of placing angioket and cream, at zero, 24 and 48 hours.The examination of the position in 24-hour intervals in terms of the occurrence and severity of phlebitis will be done by one of the researchers and one of the colleagues working in the relevant department to ensure reliability between the two evaluators. Based on the study design and ethical considerations, in both groups after examining the position using the visual scale of phlebitis in terms of its development and severity, the samples will be excluded from the study as soon as grade 2 or more phlebitis develops in them, and only samples They will remain in groups with phlebitis of 0 and 1 Phlebitis. Timepoint: Hours: 0,24,48 and 72. Method of measurement: Visual Infusion Phlebitis scale. Tehran University of Medical Sciences Approved 2023-06-28 Ethics committee in research of school of nursing midwifery rehabilitation Nosrat, Tohid, Tehran Tehran Iran (Islamic Republic of)